Logo for Gritstone bio Inc

Gritstone bio Investor Relations Material

Latest events

Logo for Gritstone bio

Q3 2023

8 Nov, 2023
Logo for Gritstone bio

Investor Presentation

31 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Gritstone bio, Inc. is a clinical-stage biotechnology company engaged in developing immunotherapies against multiple cancer types and infectious diseases. It offers, among others, SYSTIMAX, an intravenous immunotherapy for the treatment of patients with acute myeloid leukemia (AML), and other related blood cancers, and SYSTIMAX-ID, an intravenous immunotherapy for the treatment of patients with infectious diseases. Its immunotherapies include fully human monoclonal antibodies that target specific antigens associated with the surfaces of cells that drive malignancies or infection.